Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna

U.S. pharma giant Merck & Co., Inc. (NYSE: MRK) announced Tuesday ahead of the market open that it divested its direct stake in Moderna Inc (NASDAQ: MRNA) in the first half of the fourth quarter. Merck initiated a direct investment in the vaccine developer in 2015 and hiked the stake in 2018, in accordance with an R&D collaboration agreement executed between the companies.

Merck Cashes Out Direct Investment In Moderna After 600% Year-To-Date Stock Gain

BioNTech SE

Pfizer

Encouraging News on COVID-19 Vaccine

U.S. drugmaker Merck & Co said on Wednesday it had sold its equity investment in vaccine developer Moderna Inc.

Drugmaker Merck divests investment in Moderna

AbbVie

Bristol-Myers

Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.

Buffett Buys Pharma: Two Out Of Four Seem Compelling

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference

Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference

Bayer AG

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Intel

Lockheed Martin

Altria

Philip Morris

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The December 2020 Heat Map

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

Merck recently announced it is buying OncoImmune for $425 million in cash. These are the details about the deal.

Why Merck (MRK) Is Buying OncoImmune For $425 Million

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

JPMorgan Chase & Co

American Airlines

They may be down this year, but don't count these stocks out for a rally in 2021.

3 Cheap Stocks to Buy Before the Economy Makes a Full Recovery

MRK stock has entered a new swashbuckling era, searching for new profit gushers like Keytruda, the company's anti-cancer drug. The post Merck and Biotech's Swashbuckling Era appeared first on InvestorPlace.

Merck and Biotech's Swashbuckling Era

Amgen

Salesforce

Goldman Sachs

Home Depot

Johnson & Johnson

McDonald's

Microsoft

UnitedHealth Group

Dow 30,000 is great. But a Dow Jones at 31,659 is even better — and that's where the Blue Chip average is headed in 12 months, analysts say.

9 Stocks Seen Propelling Dow To 31,662

Enterprise Products Partners

Realty Income Corp

Shaw Communications

STAG Industrial

Exxon Mobil

From May to July, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 dividend equities. Kiplinger article titles were, 'Dividend15: Our Favorites'; 15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+ Year Dividends'; and '11 Monthly-Pay Stocks/Funds.'

Of 56 Kiplinger Outstanding Dividend Stocks, 11 Show Sweetness For December

Among the top 15 pharmaceutical companies by sales, Merck & Co. Inc's. (NYSE:MRK) revenue has been hit the hardest by Covid-19.

Merck Sales Hit Hardest by Pandemic

Let's see if Merck & Co (MRK) stock is a good choice for value-oriented investors right now from multiple angles.

Is Merck & Co (MRK) a Good Value Investor Stock Right Now?

The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.

Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment

Blue-chip pharmaceutical maker Merck & Co., Inc (NYSE:MRK) is struggling to gain traction this morning, down 0.3% at $80.24, following an announcement that it would acquire OncoImmune in a $425 million all-cash deal.

Merck Stock Middling After $425 Million Buyout

Merck & Co., Inc. (NYSE: MRK), which has been lagging behind some of its large-pharma peers in COVID-19 treatment and vaccine development, announced the purchase Monday of a private company with a late-stage COVID-19 treatment candidate. What Happened: Merck said it has executed a definitive agreement to buy all outstanding shares of the privately held, clinical-stage biopharma OncoImmune for an upfront payment of $425 million in cash.

Merck To Buy Late-Stage COVID-19 Treatment Company OncoImmune For $425M In Cash

Merck & Co. Inc. (NYSE: MRK) has joined the fight against COVID-19, after the company announced that it would be acquiring OncoImmune in an all-cash transaction.

Merck Joins the Fight Against COVID-19

MADISON, N.J., Nov. 23, 2020 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the US and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced a new survey about first-time dog owners and whether or not they were prepared for pet...

Merck Animal Health Survey Reveals First-Time Dog Owners Need Support

Agilent Technologies

American Equity Investment Life

Aflac

Capital City Bank Group

Core-Mark Holding Company

Matthews International

McCormick

Motorola Solutions

NIKE

Royal Gold

Spire

First Financial

In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Changes: November 14-20, 2020

Shares of Merck & Co. Inc. surged 3.1% in premarket trading Monday, after the drug maker announced a deal to buy clinical-stage biopharmaceutical company OncoImmune for an upfront payment of $425 million in cash. OncoImmune shareholders will also be eligible to receive payments based on sales payments contingent the achievement of regulatory milestones.

Merck to pay $425 million upfront to buy COVID-19 treatment developer OncoImmune

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, to the U.S. FDA and EMA

Merck Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency

The medicine, referred to as CD24Fc, was shown to reduce the risk of respiratory failure or death by more than 50% in patients hospitalized with Covid-19 and requiring oxygen

Merck acquires OncoImmune to ramp supply of promising Covid-19 drug

News for Merck Stock (MRK)